In epithelial ovarian cancer, particularly high-grade serous ovarian cancer (HGSOC), cancer antigen 125 (CA-125) is a serum glycoprotein biomarker used in standard clinical practice for the first assessment of pelvic masses [3] and for monitoring response to treatment [4,5]. This evidence concerns the gene MUC16 and ovarian serous adenocarcinoma.